PHIO (Phio Pharmaceuticals) Book Value per Share : $2.73 (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Book Value per Share?

Phio Pharmaceuticals's book value per share for the quarter that ended in Dec. 2024 was $2.73.

During the past 12 months, Phio Pharmaceuticals's average Book Value Per Share Growth Rate was -85.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -75.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -66.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Phio Pharmaceuticals was -55.30% per year. The lowest was -75.00% per year. And the median was -61.80% per year.

Phio Pharmaceuticals's current price is $1.72. Its book value per share for the quarter that ended in Dec. 2024 was $2.73. Hence, today's PB Ratio of Phio Pharmaceuticals is 0.63.

During the past 13 years, the highest P/B Ratio of Phio Pharmaceuticals was 3.59. The lowest was 0.01. And the median was 0.22.

Warning Sign:

Phio Pharmaceuticals Corp stock PB Ratio (=0.63) is close to 5-year high of 0.63.

Phio Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Phio Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Book Value per Share Chart

Phio Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Book Value per Share

Get a 7-Day Free Trial

241.06

175.46

85.34

18.58

2.73

Phio Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Book Value per Share	Get a 7-Day Free Trial															18.58	10.99	7.40	5.16	2.73

Competitive Comparison of Phio Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Phio Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's PB Ratio falls into.

Save Embed

;

Save Embed

;

Phio Pharmaceuticals Book Value per Share Calculation

Phio Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4.72	-	0.00)	/	1.73
	=	2.73

Phio Pharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4.72	-	0.00)	/	1.73
	=	2.73

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Phio Pharmaceuticals (NAS:PHIO) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Phio Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Apex Drive, Suite 300A PMB 2006, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581